West Pharmaceutical Services (United States)
WST
$362.31
-1.17%
West Pharmaceutical Services is a Pennsylvania-based supplier to the pharmaceutical, biotechnology, and generic drug industries, manufacturing elastomer-based packaging components such as stoppers, seals, and plungers, along with non-glass containment solutions and auto-injectors for injectable drugs including biologics, GLP-1 peptides, and small molecules. The company operates through two segments — proprietary products (~80% of revenue) and contract-manufactured products (~20%) — and derives roughly 55% of revenue internationally, positioning it as a critical, high-barrier-to-entry component supplier rather than a commodity packaging vendor. The current investor narrative centers on West's leverage to the GLP-1 obesity/diabetes drug boom, which drove a significant Q1 2026 earnings beat and a raised full-year guidance, as highlighted in recent Benzinga coverage. That enthusiasm is tempered by sector-wide destocking concerns — peers like CooperCompanies recently missed revenue on U.S. inventory destocking — and by West's premium valuation, leaving investors to debate whether GLP-1-driven volume growth can sustain the stock's strong multi-year re-rating.…
WST
West Pharmaceutical Services (United States)
$362.31
Related headlines
Investment Opinion: Should I buy WST Today?
The synthesized recommendation is Hold, with a bias toward accumulating on pullbacks. The core thesis is that West Pharmaceutical is a high-quality, GLP-1-levered supplier with a strong balance sheet and reaccelerating growth, but the current valuation (40.28x trailing PE, 36.32x forward PE) already prices in much of the optimism, leaving limited margin of safety. The analyst consensus is strong_buy with an average target of $405.38, implying 11.9% upside, but the wide target range ($340-$459) and premium multiple warrant caution.
Supporting evidence includes: 1) Q1 2026 revenue growth of 21.01% YoY, a sharp acceleration from ~7.5% in Q4 2025; 2) net margin expansion to 16.43% from 12.86% a year ago; 3) a debt-to-equity of 0.131 and current ratio of 3.02, reflecting minimal leverage; 4) trailing free cash flow of $458.0 million, funding dividends and buybacks; and 5) the stock's 42.09% 1-year return, significantly outperforming the S&P 500's 15.01%. However, the PEG ratio of 33.99 and EV/EBITDA of 26.97x suggest the market is paying a premium that requires sustained high growth.
The biggest risks that could invalidate the thesis are: 1) a slowdown in GLP-1 demand or renewed destocking, as seen with CooperCompanies; 2) further gross margin compression below 35%; and 3) a valuation de-rating if growth decelerates. The rating would upgrade to Buy if the stock pulls back to the $330-$340 support zone (implying a forward PE near 30x) or if revenue growth sustains above 20% for another quarter. It would downgrade to Sell if revenue growth falls below 10% or if gross margins drop below 33%. Relative to its own history (PE range 29.88x-63.05x), the stock is fairly valued to slightly overvalued, and relative to peers, it likely trades at a premium. Investors should wait for a better entry point or accumulate gradually.
Sign up to view all
WST 12-Month Price Forecast
West Pharmaceutical presents a compelling growth story tied to GLP-1 drugs, but the current valuation already reflects much of the optimism. The stock's 42% 1-year return and proximity to its 52-week high suggest limited near-term upside, while the premium multiple leaves it vulnerable to any growth disappointment. The base case (55% probability) targets $380-$410, implying modest upside from $362.31. I would upgrade to bullish if revenue growth sustains above 20% for another quarter and gross margins stabilize, or downgrade to bearish if growth decelerates below 10% or destocking pressures emerge. Given the balanced risk-reward, a neutral stance is appropriate until a better entry point emerges.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on West Pharmaceutical Services (United States)'s 12-month outlook, with a consensus price target around $405.38 and implied upside of +11.9% versus the current price.
Average Target
$405.38
0 analysts
Implied Upside
+11.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$340 - $459
Analyst target range
West Pharmaceutical is covered by 16 analysts, with a consensus recommendation of "strong_buy" and a recommendation mean of 1.41 (where 1.0 is a Strong Buy and 5.0 is a Sell). The average price target is $405.38, which implies approximately 11.9% upside from the current price of $362.31. This consensus leans bullish, supported by recent institutional actions: Barclays upgraded the stock to Overweight from Equal Weight in June 2026, and firms including Evercore ISI, KeyBanc, and Stephens & Co. maintain Outperform or Overweight ratings. The strong buy consensus, combined with the recent upgrade activity, suggests analysts see the GLP-1 growth story as durable.
The target range spans from a low of $340.00 to a high of $459.00, a spread of $119.00, or roughly 35% of the average target — indicating meaningful dispersion in analyst views. The high target of $459.00 implies about 26.7% upside and likely assumes sustained 20%+ revenue growth, multiple expansion, and successful capitalizing on GLP-1 and biologics demand. The low target of $340.00 implies roughly 6.2% downside from the current price and likely prices in margin compression, slower GLP-1 adoption, or sector-wide destocking pressures similar to those that hit CooperCompanies. The wide spread signals genuine uncertainty about the growth trajectory, and with the stock trading near its 52-week high, the risk-reward skews less favorably for new investors despite the bullish consensus.
Bulls vs Bears: WST Investment Factors
The bull case rests on West's reaccelerating revenue growth (+21% YoY in Q1 2026), pristine balance sheet (D/E 0.131), and strong analyst support (strong_buy, $405.38 average target). The bear case centers on a stretched valuation (40.28x trailing PE, 33.99 PEG), sequential gross margin compression, and sector destocking risks that could derail the growth narrative. Currently, the bull evidence is stronger given the recent earnings beat and raised guidance, but the premium multiple leaves little room for error. The single most important tension is whether the 21% revenue growth is sustainable; if it decelerates toward the high-single digits, the stock's multiple could compress sharply. Conversely, if GLP-1 demand drives sustained 20%+ growth, the premium is justified.
Bullish
- GLP-1-driven revenue acceleration: Q1 2026 revenue grew 21.01% YoY to $844.9 million, a sharp acceleration from ~7.5% YoY growth in Q4 2025 and ~7.7% in Q3 2025. This reacceleration, driven by GLP-1 demand and proprietary products, suggests West has moved past the destocking headwinds that pressured 2025 results.
- Strong analyst consensus and upside: 16 analysts rate WST a 'strong_buy' with a mean recommendation of 1.41 and an average target price of $405.38, implying 11.9% upside from $362.31. Barclays upgraded to Overweight in June 2026, reinforcing institutional confidence.
- Exceptional balance sheet strength: Debt-to-equity is just 0.131 and the current ratio is 3.02, indicating minimal leverage and ample liquidity. With $521.4 million in cash and $458.0 million in trailing free cash flow, West can fund growth, dividends, and buybacks internally.
- Improving profitability and margins: Q1 2026 net margin expanded to 16.43% from 12.86% a year earlier, while operating margin reached 20.96% and EBITDA margin 25.86%. Gross margin also improved YoY to 35.08% from 33.33%, despite a sequential dip.
Bearish
- Premium valuation with elevated PEG: The trailing PE of 40.28x and forward PE of 36.32x are rich, and the PEG ratio of 33.99 is extraordinarily high, signaling the multiple is not supported by near-term earnings growth. EV/EBITDA of 26.97x and P/S of 6.47x also reflect a premium.
- Gross margin compression risk: Gross margin declined sequentially to 35.08% in Q1 2026 from 37.75% in Q4 2025 and 36.49% in Q3 2025, suggesting mix or cost pressures. If this trend continues, it could undermine the earnings growth needed to justify the valuation.
- Destocking headwinds persist in sector: Peer CooperCompanies recently missed revenue due to U.S. inventory destocking, sending its stock down 16% after-hours. This highlights that sector-wide inventory corrections remain a live risk that could spill over to West's orders.
- Stock near 52-week high limits margin of safety: At $362.31, WST trades at ~85.4% of its 52-week range (low $223.83, high $386.00) and just 6.5% below the high. With beta of 1.135 and a max drawdown of -24.83%, the risk-reward for new entries is less favorable.
WST Technical Analysis
West Pharmaceutical is in a sustained uptrend, with the stock up 42.09% over the past year and 31.08% year-to-date, decisively outperforming the S&P 500's 15.01% and 11.70% respective gains. At a current price of $362.31, the stock sits at approximately 85.4% of its 52-week range (low of $223.83, high of $386.00), reflecting strong momentum but also proximity to overhead resistance. This positioning near the upper end of the range signals that buyers remain in control, though the stock is no longer in the deep-value zone that existed near the 52-week low earlier in the period. The 6-month gain of 52.85% underscores the sheer velocity of the move, which raises the risk of profit-taking or consolidation before a fresh breakout attempt at the $386 high.
Recent momentum remains constructive but is decelerating relative to the longer-term trend. The 1-month change of 2.70% and 3-month change of 10.48% are positive but well below the 6-month gain of 52.85%, indicating the pace of appreciation has cooled considerably from the spring surge. Notably, the 1-month relative strength versus SPY is +3.66%, and the 3-month relative strength is +8.48%, confirming West continues to outperform even as absolute momentum moderates. The stock's beta of 1.135 suggests it moves roughly 13.5% more than the market, so the recent consolidation is not unusual for a high-beta name digesting a large advance. The short ratio of 4.33 days indicates moderate short interest, not enough to fuel a squeeze but sufficient to add volatility on upside surprises.
Key technical levels are well-defined: support rests near the 52-week low of $223.83, with intermediate support likely around the $330–$340 zone where the stock consolidated in July and August 2026, while resistance sits at the 52-week high of $386.00. A breakout above $386 would confirm the uptrend's continuation and likely invite momentum buyers targeting new highs, whereas a breakdown below $330 could signal a deeper mean-reversion toward the $300 area. The maximum drawdown of -24.83% over the period is a reminder that this stock can correct sharply despite its quality profile, and with beta at 1.135, position sizing should account for above-market volatility. The current price of $362.31 is only about 6.5% below the 52-week high, so the risk-reward for new entries is less favorable than it was at lower levels.
Beta
1.14
1.14x market volatility
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$224-$386
Price range past year
Annual Return
+42.1%
Cumulative gain past year
| Period | WST Return | S&P 500 |
|---|---|---|
| 1m | +2.7% | -0.5% |
| 3m | +10.5% | +2.3% |
| 6m | +52.9% | +16.6% |
| 1y | +42.1% | +14.8% |
| ytd | +31.1% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WST Fundamental Analysis
West's revenue trajectory is clearly re-accelerating, with Q1 2026 revenue of $844.9 million representing 21.01% year-over-year growth versus Q1 2025's $698.2 million. This marks a sharp acceleration from the prior quarters: Q4 2025 revenue of $805.0 million grew roughly 7.5% YoY over Q4 2024's $748.5 million, while Q3 2025's $804.3 million grew about 7.7% over Q3 2024's $746.9 million. The Q1 2026 jump, driven by GLP-1 demand and the proprietary products segment contributing $694.3 million, suggests the company has moved past the destocking headwinds that pressured 2025 results. If this growth rate is sustained, it materially strengthens the investment case and supports the raised guidance management issued in April 2026.
Profitability is robust and improving, with Q1 2026 net income of $138.8 million on a 16.43% net margin, up from $89.8 million and a 12.86% net margin in Q1 2025. Gross margin, however, compressed to 35.08% in Q1 2026 from 37.75% in Q4 2025 and 36.49% in Q3 2025, though it remains above the 33.33% recorded in Q1 2025 — suggesting some mix or cost pressure but a favorable year-over-year trend. Operating margin of 20.96% in Q1 2026 is healthy for the medical instruments and supplies industry, and EBITDA of $218.5 million (25.86% EBITDA margin) reflects solid operating leverage. The sequential gross margin decline warrants monitoring, but the overall profitability profile is consistent with a high-quality, niche supplier.
The balance sheet is exceptionally strong, with a debt-to-equity ratio of just 0.131 and a current ratio of 3.02, indicating ample liquidity and minimal leverage risk. Free cash flow on a trailing twelve-month basis is $458.0 million, though Q1 2026 free cash flow of $47.2 million was depressed by $297.6 million in stock repurchases and $42.7 million in capital expenditures against $89.9 million in operating cash flow. Return on equity of 15.54% and return on assets of 11.38% demonstrate efficient capital deployment, while the cash balance of $521.4 million provides ample dry powder. The company generates sufficient internal cash to fund growth, dividends ($15.8 million paid in Q1 2026), and buybacks without relying on external financing, a hallmark of financial resilience.
Quarterly Revenue
$844900000.0B
2026-03
Revenue YoY Growth
+21.0%
YoY Comparison
Gross Margin
35.1%
Latest Quarter
Free Cash Flow
$458000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WST Overvalued?
Because West Pharmaceutical is profitable — Q1 2026 net income of $138.8 million and trailing EPS positive — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 40.28x and a forward PE of 36.32x, with the gap implying the market expects meaningful earnings growth over the next twelve months. The forward PE compression of roughly 10% suggests analysts anticipate EPS expansion, consistent with the consensus estimated EPS of $14.01 for the coming year. However, the PEG ratio of 33.99 is extraordinarily elevated, signaling that the current multiple is not supported by the expected earnings growth rate on a near-term basis.
Relative to the broader medical instruments and supplies sector, West's valuation appears rich, though precise industry averages are not provided in the data. The price-to-sales ratio of 6.47x, price-to-book of 6.26x, and EV/EBITDA of 26.97x all point to a premium multiple, while the EV/Sales of 7.72x and price-to-cash-flow of 26.35x reinforce that investors are paying up for quality and growth. The net margin of 16.06% and operating margin of 20.09% are solid but not exceptional enough to fully justify such a premium on their own — the premium is more likely tied to West's GLP-1 exposure and the durability of its proprietary products franchise. Whether this premium is justified depends on whether the 21% revenue growth seen in Q1 2026 proves sustainable.
Historically, West's PE has ranged widely: it was 32.47x in Q1 2026, 37.59x in Q4 2025, 45.14x in Q1 2025, and as high as 63.05x in Q1 2024, with a low of 29.88x in Q2 2022. At 40.28x trailing, the current multiple sits in the middle-to-upper portion of its multi-year band — below the 2024 peak but above the 2022 trough. The PS ratio of 6.47x is notably below the 21.36x recorded in Q1 2026 historical data (which appears to reflect a different share count or data convention) and well below the 31.95x seen in Q4 2024, suggesting the stock is not at historical valuation extremes on a sales basis. Overall, the valuation embeds optimistic expectations for GLP-1-driven growth, leaving limited margin for execution missteps.
PE
40.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 30x~53x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. West's debt-to-equity of 0.131 and current ratio of 3.02 indicate a fortress balance sheet, but the company's Q1 2026 free cash flow of $47.2 million was depressed by $297.6 million in stock repurchases and $42.7 million in capex, against $89.9 million in operating cash flow. This suggests that buybacks are consuming a large portion of cash generation, which could limit flexibility if growth investments are needed. Additionally, gross margin compression to 35.08% in Q1 2026 from 37.75% in Q4 2025, if sustained, could pressure profitability and earnings growth, especially given the high valuation multiple. Revenue concentration in proprietary products (~80%) and reliance on GLP-1 demand also pose operational risks if that therapeutic area faces pricing pressure or regulatory changes.
Market and competitive risks are significant given the premium valuation. WST trades at a trailing PE of 40.28x and EV/EBITDA of 26.97x, well above the broader market and likely above many medical supply peers. With a beta of 1.135, the stock is more volatile than the market, and any sector rotation away from high-multiple healthcare names could trigger a sharp de-rating. The recent CooperCompanies revenue miss on destocking highlights that inventory corrections remain a sector-wide threat, and West's 55% international exposure adds currency and geopolitical risk. Regulatory changes affecting drug pricing or GLP-1 reimbursement could also dampen demand for West's components. The wide analyst target range ($340-$459) underscores the uncertainty around growth durability.
In a worst-case scenario, a combination of decelerating GLP-1 demand, renewed destocking, and margin compression could lead to a significant de-rating. If revenue growth slows to high-single digits and the PE compresses toward the lower end of its historical range (e.g., 30x), the stock could fall toward the analyst low target of $340, implying ~6% downside. A more severe scenario, such as a broad healthcare selloff or a major customer loss, could push the stock toward its 52-week low of $223.83, representing a 38% decline from the current price of $362.31. Given the max drawdown of -24.83% over the past period, investors should be prepared for volatility; a realistic bear-case downside is -15% to -25%, targeting the $270-$310 range.
FAQ
The key risks include: 1) Valuation risk — the stock trades at 40.28x trailing earnings and 26.97x EV/EBITDA, leaving it vulnerable to de-rating if growth slows; 2) Sector destocking — peer CooperCompanies recently missed revenue on U.S. inventory destocking, a risk that could spread to West; 3) Margin compression — gross margin fell sequentially to 35.08% in Q1 2026 from 37.75% in Q4 2025, and further declines could pressure earnings; 4) GLP-1 concentration — while a growth driver, any slowdown in GLP-1 demand or regulatory changes could significantly impact West's proprietary products segment. These risks are ranked from highest to lowest severity, with valuation and destocking being the most immediate concerns.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $430-$459, assuming sustained 20%+ revenue growth and multiple expansion; Base case (55% probability) targets $380-$410, assuming mid-teens growth and stable margins; Bear case (20% probability) targets $280-$340, assuming growth decelerates to high-single digits and margins compress. The base case is most likely, supported by the analyst average target of $405.38 and the company's strong Q1 2026 performance. The key assumption is that GLP-1 demand remains robust and destocking does not re-emerge. If growth accelerates, the bull case could play out; if it falters, the bear case becomes relevant.
WST appears slightly overvalued on most metrics. The trailing PE of 40.28x and forward PE of 36.32x are above the broader market and near the upper end of its historical range (29.88x to 63.05x). The PEG ratio of 33.99 is extraordinarily high, indicating the multiple is not supported by near-term earnings growth. EV/EBITDA of 26.97x and P/S of 6.47x also reflect a premium. The market is pricing in sustained 20%+ growth, so any deceleration could lead to multiple compression. Compared to peers, WST likely trades at a premium due to its GLP-1 exposure and high barriers to entry, but the valuation leaves little margin of safety.
WST is a good buy for growth-oriented investors with a long-term horizon, but the current entry point is less attractive after a 42% one-year rally. The stock trades at $362.31, just 6.5% below its 52-week high, and the analyst average target of $405.38 implies only 11.9% upside. The biggest downside risk is a growth slowdown or destocking event that could push the stock toward $340 or lower. For those willing to tolerate volatility (beta 1.135), accumulating on pullbacks to the $330-$340 support zone would offer a better risk-reward. Overall, it is a quality holding but not a screaming bargain at these levels.
WST is better suited for long-term investment (minimum 2-3 years) given its growth stage, high barriers to entry, and exposure to secular trends like GLP-1 drugs and biologics. The stock's beta of 1.135 and max drawdown of -24.83% indicate above-average volatility, making it less ideal for short-term trading unless one actively manages risk. The dividend yield is minimal at 0.31%, so returns depend primarily on capital appreciation. Earnings visibility is moderate, with analyst EPS estimates of $14.01 for the coming year, but quarterly fluctuations can be sharp. A long-term holder can ride out destocking cycles and benefit from the company's structural growth, while short-term traders should watch technical levels like $386 resistance and $330 support.